From the American College of Physicians and University of Pennsylvania Health System, Philadelphia, Pennsylvania; Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota; Community Care of the Lower Cape Fear, Wilmington, North Carolina; Oregon Health & Science University, Portland, Oregon; and American Academy of Family Physicians, Leawood, Kansas.
Ann Intern Med. 2017 Mar 21;166(6):430-437. doi: 10.7326/M16-1785. Epub 2017 Jan 17.
The American College of Physicians (ACP) and the American Academy of Family Physicians (AAFP) jointly developed this guideline to present the evidence and provide clinical recommendations based on the benefits and harms of higher versus lower blood pressure targets for the treatment of hypertension in adults aged 60 years or older.
This guideline is based on a systematic review of published randomized, controlled trials for primary outcomes and observational studies for harms only (identified through EMBASE, the Cochrane Database of Systematic Reviews, MEDLINE, and ClinicalTrials.gov), from database inception through January 2015. The MEDLINE search was updated through September 2016. Evaluated outcomes included all-cause mortality, morbidity and mortality related to stroke, major cardiac events (fatal and nonfatal myocardial infarction and sudden cardiac death), and harms. This guideline grades the evidence and recommendations using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) method.
The target audience for this guideline includes all clinicians, and the target patient population includes all adults aged 60 years or older with hypertension.
RECOMMENDATION 1: ACP and AAFP recommend that clinicians initiate treatment in adults aged 60 years or older with systolic blood pressure persistently at or above 150 mm Hg to achieve a target systolic blood pressure of less than 150 mm Hg to reduce the risk for mortality, stroke, and cardiac events. (Grade: strong recommendation, high-quality evidence). ACP and AAFP recommend that clinicians select the treatment goals for adults aged 60 years or older based on a periodic discussion of the benefits and harms of specific blood pressure targets with the patient.
RECOMMENDATION 2: ACP and AAFP recommend that clinicians consider initiating or intensifying pharmacologic treatment in adults aged 60 years or older with a history of stroke or transient ischemic attack to achieve a target systolic blood pressure of less than 140 mm Hg to reduce the risk for recurrent stroke. (Grade: weak recommendation, moderate-quality evidence). ACP and AAFP recommend that clinicians select the treatment goals for adults aged 60 years or older based on a periodic discussion of the benefits and harms of specific blood pressure targets with the patient.
RECOMMENDATION 3: ACP and AAFP recommend that clinicians consider initiating or intensifying pharmacologic treatment in some adults aged 60 years or older at high cardiovascular risk, based on individualized assessment, to achieve a target systolic blood pressure of less than 140 mm Hg to reduce the risk for stroke or cardiac events. (Grade: weak recommendation, low-quality evidence). ACP and AAFP recommend that clinicians select the treatment goals for adults aged 60 years or older based on a periodic discussion of the benefits and harms of specific blood pressure targets with the patient.
美国医师学院(ACP)和美国家庭医师学会(AAFP)共同制定了本指南,旨在根据治疗 60 岁或以上成年人高血压的较高与较低血压目标的获益和危害,提供证据并提出临床建议。
本指南基于对已发表的随机对照试验的系统评价,主要结局为初级结局,危害仅基于观察性研究(通过 EMBASE、Cochrane 系统评价数据库、MEDLINE 和 ClinicalTrials.gov 确定),从数据库建立到 2015 年 1 月。2016 年 9 月更新了 MEDLINE 检索。评估的结局包括全因死亡率、与卒中相关的发病率和死亡率、主要心脏事件(致命和非致命性心肌梗死和心源性猝死)以及危害。本指南使用 GRADE(推荐分级的评估、制定与评价)方法对证据和建议进行分级。
本指南的目标受众包括所有临床医生,目标患者人群包括所有 60 岁或以上患有高血压的成年人。
建议 1:ACP 和 AAFP 建议临床医生对持续性收缩压在 150mmHg 或以上的 60 岁或以上成年人开始治疗,以将收缩压目标值降至 150mmHg 以下,从而降低死亡率、卒中以及心脏事件风险。(强烈推荐,高质量证据)。ACP 和 AAFP 建议临床医生根据与患者定期讨论特定血压目标的获益和危害,为 60 岁或以上成年人选择治疗目标。
建议 2:ACP 和 AAFP 建议对有卒中或短暂性脑缺血发作史的 60 岁或以上成年人考虑起始或强化药物治疗,以将收缩压目标值降至 140mmHg 以下,从而降低复发性卒中风险。(弱推荐,中等质量证据)。ACP 和 AAFP 建议临床医生根据与患者定期讨论特定血压目标的获益和危害,为 60 岁或以上成年人选择治疗目标。
建议 3:ACP 和 AAFP 建议基于个体化评估,对某些 60 岁或以上的高心血管风险成年人考虑起始或强化药物治疗,以将收缩压目标值降至 140mmHg 以下,降低卒中或心脏事件风险。(弱推荐,低质量证据)。ACP 和 AAFP 建议临床医生根据与患者定期讨论特定血压目标的获益和危害,为 60 岁或以上成年人选择治疗目标。